
OVIZIO raises 5M€ in Series A financing

Date 12 December 2011

Release Immediate

The company will utilize the funds to accelerate its product development plans and increase its international commercial presence.

Ovizio, a spin-off company of the Université Libre de Bruxelles, founded by Serge Jooris (CTO) and Philip Mathuis (CEO) in December 2009 has secured a Series A funding of 5M€ that will be used to accelerate its product development pipeline and to launch its international expansion.

The company develops a new-patented 3D microscopy technology based on Digital Holography invented by co-founders Professor Frank Dubois and Dr. Catherine Yourassowsky from the University. The breakthrough platform is used in life science research, bioprocessing and diagnostics and has already been adopted by global pharmaceutical and biotechnology leaders.

Ovizio was launched in December 2009 with seed funding from the founding team, the University's Theodorus II fund and the SRIB (Société Régionale d'Investissement de Bruxelles). The company also received R&D grants from Innoviris, the Brussels Institute for Research and Innovation.

Ovizio, assisted by GoNext, has chosen an entrepreneurial led investor consortium around two venture funds (Sherpa Invest II – BAMS Angel fund) completed with two industrial partners, private investors and its historical partners.

Philip Mathuis, CEO of Ovizio, said: "We are very excited to have such an outstanding syndicate of investors that appreciate and understand the potential of our technology. The financial support that we have received will allow us to expand our efforts in developing a platform technology and commercial organization that address unmet needs in our markets."

Serge Jooris, CTO of Ovizio, said: "This investment will allow us to strengthen our core R&D team and to focus our efforts on reducing the size and footprint of our technology allowing us to build products that will help our clients increase their productivity and accelerate their discovery capabilities".

Jean Van Nuwenborg, Partner of the Theodorus II investment fund, said: "Ovizio combines the key success factors of any spin-off with global ambitions: outstanding science, an experienced management team, important and global market needs and solid, added-value financial partners. We are convinced Ovizio will set the standard for future spin-offs".

- Ends -

About Ovizio

Ovizio Imaging Systems SA NV
Rue Engelandstraat 555
B-1180 Bruxelles
Belgium

T +32 2 600 50 90
F +32 2 600 50 45
info@ovizio.com
www.ovizio.com

VAT BE 821 638 597
IBAN: BE71 0688 8966 8869
BIC: GKCCBEBB
Social Security 1353168-42

Ovizio is an innovative spin-off company of the Free University of Brussels (ULB). The company designs, develops and markets 3-D imaging systems and sensors based on patented Digital Holographic Microscopy with a primary focus on the Life Science Research and bioprocessing industry.

Ovizio's Imaging Devices unify 3D real-time quantitative imaging with speed and a non-invasive, label-free approach. Our advanced technology generates high quality holographic images ideal for studying dynamic phenomena, breaking the barriers between flow cytometry and classic microscopy.

Ovizio is a privately held company situated in Brussels, Belgium. For additional information, visit www.ovizio.com.

For further information please contact:

Philip Mathuis

CEO

M +32 476 88 01 72

philip@ovizio.com